The findings of the SURPASS-CVOT study reveal that tirzepatide is not inferior to dulaglutide in lowering the risk of major adverse cardiovascular events (MACE-3) in patients with type 2 diabetes and cardiovascular disease. Notably, tirzepatide demonstrated an 8% risk reduction and a significant 16% reduction in all-cause mortality. Conducted over a period of 4.5 years, this extensive study included over 13,000 patients. The results underscore tirzepatide's superiority over dulaglutide in managing A1C levels, weight control, renal function protection, and the enhancement of cardiovascular biomarkers, all while maintaining an excellent safety profile. This groundbreaking study offers vital clinical insights for diabetes treatment in China and worldwide, poised to propel the widespread clinical adoption of tirzepatide.